Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: March 21, 2008
Last updated: October 18, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 23, 2012